Besides the aforementioned early warrant conversion offering... I have been looking for clues that December 5th could be that first big day...

1.Change in titles:  To me the change from “downregulates” to” corrects” is interesting:

 The 2018 AD/PD meeting in Portugal : The Epigenetic Inhibitor Apabetalone Downregulates Brain Endothelial and Microglial Cell Activation that Contributes To Neurodegenerative Disease

 2019 CTD meeting (Next week!): The epigenetic inhibitor APABETALONE corrects pathophysiological brain endothelial and microglial cell activation that contributes to neurodegenerative disease

2.We should not be underpowered here, more than four times the number needed in each arm to prove efficacy:

 From Congnition subgroup poster:

MoCA score change from historical data shows a standard deviation of 3.2 points predicting a necessary sample size of 54 subjects per arm to provide a 90% power to detect a mean between group difference of 2 points at p<0.05.

     BETonMace:         N =469 Patients Completed Baseline MoCA

                                       N=246 Patients with Baseline MoCA ≤ 25

 https://www.resverlogix.com/upload/media_element/173/b9738b92dd21/2019-07-08---aaic-poster-2019-final.pdf

3. Attendees: Zetterberg, Kulikowski, and Cummings all prominent headliners on the RVX Poster for the cognition subgroup data... Winblad and DeCarli are big names as well,  not on the RVX research team. 

  Pretty big names speaking about epigenetics and AD at 4pm Paciific time, on December5th.  

Six more days, passing time, and these were 3 things that jumped out at me...  GLTA